Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.7% – Should You Sell?

Posted by Stanley Muller on Oct 2nd, 2026

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)’s share price was down 5.7% during mid-day trading on Friday. The stock traded as low as $44.76 and last traded at $44.32. 1,013,856 shares were traded during mid-day trading, a decline of 6% from the average daily volume of 1,077,279 shares. The stock had previously closed at $46.99.

Nektar Therapeutics News Summary

Here are the key news stories impacting Nektar Therapeutics this week:

Positive Sentiment: Long-term Phase 2b results showed that rezpegaldesleukin’s benefits may persist after treatment ends. In alopecia areata, 75% of responding patients maintained a SALT score of 20 or below four months off treatment, while 63% maintained that response at six months. Hair regrowth also continued after treatment, with 19% reaching a SALT score of 10 or below. New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement
Positive Sentiment: Nektar is advancing the program toward pivotal testing: a third Phase 3 ZENITH trial in treatment-experienced atopic dermatitis has begun, and the Phase 3 ZENITH alopecia areata study is expected to start in early 2027. Nektar Reports Durable Rezpegaldesleukin Data
Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $185 price target, implying substantial upside from recent trading levels. This is an analyst forecast, not a guarantee of performance.
Neutral Sentiment: New biomarker findings indicated early effects across multiple immune pathways in atopic dermatitis, potentially supporting rezpegaldesleukin’s differentiated Treg-based mechanism. New Biomarker Data Presented at EADV Congress 2026
Negative Sentiment: The positive dermatology update did not immediately translate into a stronger stock reaction. Investors may be demanding clearer pivotal-trial evidence and a nearer-term commercial path, since the reported results are still Phase 2b data and Phase 3 readouts remain outstanding. Nektar Drops After New Mid-Stage Data

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on NKTR. Canaccord Genuity Group started coverage on Nektar Therapeutics in a research report on Wednesday, July 22nd. They set a “buy” rating and a $153.00 price objective for the company. TD Cowen raised Nektar Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright reiterated a “buy” rating and issued a $185.00 price target on shares of Nektar Therapeutics in a research report on Friday. BTIG Research reissued a “buy” rating and issued a $178.00 price target on shares of Nektar Therapeutics in a research note on Friday, September 25th. Finally, JPMorgan Chase & Co. started coverage on shares of Nektar Therapeutics in a research note on Friday, August 21st. They set a “neutral” rating and a $65.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $138.50.

Read Our Latest Stock Analysis on NKTR

Nektar Therapeutics Price Performance

The stock has a fifty day moving average price of $70.09 and a 200-day moving average price of $71.25. The company has a market cap of $1.51 billion, a PE ratio of -6.64 and a beta of 1.26.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.97) by $0.74. The business had revenue of $10.13 million for the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative return on equity of 37.87% and a negative net margin of 287.84%. On average, equities analysts anticipate that Nektar Therapeutics will post -8.16 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Howard Robin sold 418 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the transaction, the chief executive officer owned 54,627 shares in the company, valued at $3,932,051.46. This represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in Nektar Therapeutics during the first quarter worth approximately $52,000. FNY Investment Advisers LLC raised its position in shares of Nektar Therapeutics by 15.8% in the second quarter. FNY Investment Advisers LLC now owns 5,500 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 750 shares during the period. State of Wyoming bought a new position in shares of Nektar Therapeutics in the first quarter valued at approximately $67,000. Arizona State Retirement System lifted its stake in shares of Nektar Therapeutics by 27.3% in the second quarter. Arizona State Retirement System now owns 8,477 shares of the biopharmaceutical company’s stock worth $592,000 after buying an additional 1,816 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Nektar Therapeutics by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 10,729 shares of the biopharmaceutical company’s stock worth $771,000 after buying an additional 2,629 shares during the period. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that use the body’s immune system to treat cancer and autoimmune diseases. The company’s research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents.

Nektar’s pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses.